Biotechnology and pharmaceutical sector attracts investor interest in covid

The weight of the biotechnology and pharmaceutical sector has grown to 16% of the investments made this year by private investors and, on the contrary, the finance and banking and consumer goods sector seem to be the main ones affected by the pandemic.

This data is contained in the latest report “Business Angels 2020. La inversión en startups: actividad y tendencias” by the Spanish Association of Business Angels Networks (Aeban), which was presented this Thursday by the association’s vice-president, Regina Llopis, at the sixth National Congress organised by BIGBAN Inversores Privados de València, which is being held digitally this year.

The health sector, which will grow significantly in 2019, has derived part of the interest of investors in the first months of this year towards the biotechnology and pharmacy segment. These two, together with software, have been the most attractive for private investment. As a result of the pandemic, 42% of those surveyed believe that they will make fewer investments, 28% do not expect to reduce them and 30% maintain an indefinite position, while 64% rule out investment in “startups” in sectors sensitive to covid-19, which will be the main victims of the crisis.

More information at Economía 3